Rocket receives $150m credit facility to advance cardiovascular portfolio

Rocket Pharmaceuticals develops genetic medicines for rare as well as life-threatening diseases, with a focus on cardiovascular disorders. Credit: NMK-Studio/Shutterstock.com.